Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is Routine Interruption of Direct Oral Anticoagulants Necessary during Colorectal Endoscopic Mucosal Resection and Hot Snare Polypectomy? A Multicenter Propensity-Matched Study.

Journal of gastroenterology and hepatology·2026
Same author

Revisiting nursing- and healthcare-associated pneumonia in Japan: Microbiology, multidrug resistance, and clinical outcomes compared with community-acquired pneumonia.

Respiratory investigation·2026
Same author

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

European urology·2026
Same author

Clinical Significance of Serum (1→3)-β-D-Glucan Positivity in Cryptococcosis: A Retrospective Cohort Study.

Journal of fungi (Basel, Switzerland)·2026
Same author

Transcranial Transvenous Embolization with Onyx through a Steerable Catheter for a Dural Arteriovenous Fistula of the Isolated Superior Sagittal Sinus: A Technical Case Report.

NMC case report journal·2026
Same author

Clinical significance of <sup>18</sup>F-FDG uptake in interstitial lung lesions in lung cancer patients with interstitial lung disease treated with immune checkpoint inhibitor therapy.

Respiratory investigation·2026

Related Experiment Video

Updated: Apr 15, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Emerging immunotherapies for bladder cancer.

Joseph W Kim1, Yusuke Tomita, Jane Trepel

  • 1aProstate and Urologic Cancers Program, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut bDevelopmental Therapeutics Branch cGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Current Opinion in Oncology
|March 27, 2015
PubMed
Summary

Emerging immunotherapies show promise for advanced urothelial carcinoma by targeting immune escape. Further research into overcoming resistance mechanisms is crucial to expand patient access to these treatments.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.3K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K

Related Experiment Videos

Last Updated: Apr 15, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.3K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K

Area of Science:

  • Oncology
  • Immunology
  • Urothelial Carcinoma Research

Background:

  • Urothelial carcinoma exhibits high mutational burden, potentially increasing tumor antigen recognition.
  • However, it employs immune evasion strategies like downregulating antigen presentation and upregulating immune checkpoints.
  • These mechanisms inactivate cytotoxic T cells, hindering anti-tumor immunity.

Purpose of the Study:

  • To review emerging immunotherapies for urothelial carcinoma.
  • To discuss agents in various stages of clinical development.
  • To highlight the role of inhibiting immune escape mechanisms, such as the programed death-ligand 1 pathway.

Main Methods:

  • Review of clinical trial data for immunotherapies in urothelial carcinoma.
  • Analysis of immune escape mechanisms in urothelial carcinoma.
  • Discussion of emerging therapeutic strategies targeting these mechanisms.

Main Results:

  • Immunotherapies targeting immune escape pathways demonstrate activity in urothelial carcinoma.
  • These treatments have shown rapid and durable responses in some patients.
  • Many novel immunotherapeutic agents are currently in clinical trials for this cancer type.

Conclusions:

  • Immunotherapies are active in urothelial carcinoma but benefit only a subset of patients.
  • Persistent immune escape mechanisms limit treatment efficacy.
  • Identifying resistance mechanisms and developing combination therapies are key to broadening patient benefit.